This article is part of the supplement: Italian Society of Bioinformatics (BITS): Annual Meeting 2005

Open Access Research article

An integrated approach of immunogenomics and bioinformatics to identify new Tumor Associated Antigens (TAA) for mammary cancer immunological prevention

Federica Cavallo1, Annalisa Astolfi3, Manuela Iezzi4, Francesca Cordero12, Pier-Luigi Lollini3, Guido Forni1 and Raffaele Calogero1*

Author Affiliations

1 Dept. of Clinical and Biological Sciences, University of Torino, Az. Ospedaliera S. Luigi, Regione Gonzole 10, I-10043 Orbassano Italy

2 Dept. of Informatics, University of Torino, Via Pessinetto 12, I-10100 Torino, Italy

3 Dept. of Experimental Pathology, University of Bologna, Viale Filopanti 22, I-40126 Bologna, Italy

4 Dept. of Oncology and Neurosciences, University of Chieti, Via Colle dell'Ara, I-66013 Chieti, Italy

For all author emails, please log on.

BMC Bioinformatics 2005, 6(Suppl 4):S7  doi:10.1186/1471-2105-6-S4-S7

Published: 1 December 2005



Neoplastic transformation is a multistep process in which distinct gene products of specific cell regulatory pathways are involved at each stage. Identification of overexpressed genes provides an unprecedented opportunity to address the immune system against antigens typical of defined stages of neoplastic transformation. HER-2/neu/ERBB2 (Her2) oncogene is a prototype of deregulated oncogenic protein kinase membrane receptors. Mice transgenic for rat Her2 (BALB-neuT mice) were studied to evaluate the stage in which vaccines can prevent the onset of Her2 driven mammary carcinomas. As Her2 is not overexpressed in all mammary carcinomas, definition of an additional set of tumor associated antigens (TAAs) expressed at defined stages by most breast carcinomas would allow a broader coverage of vaccination. To address this question, a meta-analysis was performed on two transcription profile studies [1,2] to identify a set of new TAA targets to be used instead of or in conjunction with Her2.


The five TAAs identified (Tes, Rcn2, Rnf4, Cradd, Galnt3) are those whose expression is linearly related to the tumor mass increase in BALB-neuT mammary glands. Moreover, they have a low expression in normal tissues and are generally expressed in human breast tumors, though at a lower level than Her2.


Although the number of putative TAAs identified is limited, this pilot study suggests that meta-analysis of expression profiles produces results that could assist in the designing of pre-clinical immunopreventive vaccines.